Axim Biotechnologies Valuation
| AXIM Stock | USD 0 0.0001 5.00% |
Axim Biotechnologies seems to be fairly valued based on Macroaxis valuation methodology. Our model approximates the value of Axim Biotechnologies from analyzing the firm fundamentals such as Return On Equity of -100.19, shares outstanding of 186.44 M, and Operating Margin of (847.86) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Axim Biotechnologies' price fluctuation is out of control at this time. Calculation of the real value of Axim Biotechnologies is based on 3 months time horizon. Increasing Axim Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Axim pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Axim Biotechnologies. Since Axim Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Axim Pink Sheet. However, Axim Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0021 | Real 0.002016 | Hype 0.002273 | Naive 0.001524 |
The intrinsic value of Axim Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Axim Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Axim Biotechnologies helps investors to forecast how Axim pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Axim Biotechnologies more accurately as focusing exclusively on Axim Biotechnologies' fundamentals will not take into account other important factors: Axim Biotechnologies Total Value Analysis
Axim Biotechnologies is presently forecasted to have valuation of 13.6 M with market capitalization of 4.64 M, debt of 5.06 M, and cash on hands of 65.16 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Axim Biotechnologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.6 M | 4.64 M | 5.06 M | 65.16 K |
Axim Biotechnologies Investor Information
About 41.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.13. Axim Biotechnologies had not issued any dividends in recent years. Based on the key indicators related to Axim Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Axim Biotechnologies is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Axim Biotechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Axim Biotechnologies has an asset utilization ratio of 1.14 percent. This suggests that the Company is making $0.0114 for each dollar of assets. An increasing asset utilization means that Axim Biotechnologies is more efficient with each dollar of assets it utilizes for everyday operations.Axim Biotechnologies Ownership Allocation
Axim Biotechnologies holds a total of 186.44 Million outstanding shares. Axim Biotechnologies retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Axim Biotechnologies Profitability Analysis
The company reported the previous year's revenue of 60.46 K. Net Loss for the year was (16.03 M) with profit before overhead, payroll, taxes, and interest of 60.46 K.About Axim Biotechnologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Axim Biotechnologies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Axim Biotechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Axim Biotechnologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Axim Biotechnologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Axim Biotechnologies. We calculate exposure to Axim Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Axim Biotechnologies's related companies.AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.
8 Steps to conduct Axim Biotechnologies' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Axim Biotechnologies' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Axim Biotechnologies' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Axim Biotechnologies' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Axim Biotechnologies' revenue streams: Identify Axim Biotechnologies' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Axim Biotechnologies' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Axim Biotechnologies' growth potential: Evaluate Axim Biotechnologies' management, business model, and growth potential.
- Determine Axim Biotechnologies' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Axim Biotechnologies' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Axim Biotechnologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Axim Biotechnologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 138.1 M | |
| Retained Earnings | -57.9 M |
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.